Todd M. Baughman

Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.

Anne H. Dantzig, Robert L. Shepard, Jin Cao et al. · PubMed · 1996 · 327 citations

Pharmaceutical Science, Pharmacotherapy, Chemical Biology +19

Pharmacological characterization of LY335979: A potent cyclopropyldibenzosuberane modulator of P-glycoprotein

James J. Starling, Robert L. Shepard, Jin Cao et al. · Advances in Enzyme Regulation · 1997 · 86 citations

Molecular Pharmacology, Pharmacological Characterization, Biochemistry +6

P‐glycoprotein Influences the Brain Concentrations of Cetirizine (Zyrtec®), a Second‐Generation Non‐Sedating Antihistamine

Joseph W. Polli, Todd M. Baughman, Joan E. Humphreys et al. · Journal of Pharmaceutical Sciences · 2003 · 85 citations

Second‐generation Non‐sedating Antihistamine, Neurobiology Of Disease, Neurophysiology +10

METABOLIC ACTIVATION OF PIOGLITAZONE IDENTIFIED FROM RAT AND HUMAN LIVER MICROSOMES AND FRESHLY ISOLATED HEPATOCYTES

Todd M. Baughman, Rachel Graham, Kevin J. Wells‐Knecht et al. · Drug Metabolism and Disposition · 2005 · 41 citations

Liquid chromatography/nuclear magnetic resonance spectroscopy and liquid chromatography/mass spectrometry identification of novel metabolites of the multidrug resistance modulator LY335979 in rat bile and human liver microsomal incubations.

William J. Ehlhardt, Joseph M. Woodland, Todd M. Baughman et al. · PubMed · 1998 · 40 citations

Metabolomic Profiling, Medicinal Chemistry, Novel Metabolites +20